These studies, therefore, strongly suggest that pharmacological stimulation of TRPV1 could represent an alternative strategy to induce therapeutic angiogenesis in ischemic tissues, even in the presence of established cardiovascular risk factors, e.g., hyperlipidemia. Here, TRPV1 is linked to hyperlipidemia.